These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 27125390)

  • 1. Pathogenesis of Cardiovascular and Metabolic Diseases: Are Fructose-Containing Sugars More Involved Than Other Dietary Calories?
    Rosset R; Surowska A; Tappy L
    Curr Hypertens Rep; 2016 Jun; 18(6):44. PubMed ID: 27125390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sugar consumption, metabolic disease and obesity: The state of the controversy.
    Stanhope KL
    Crit Rev Clin Lab Sci; 2016; 53(1):52-67. PubMed ID: 26376619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fructose and Cardiometabolic Health: What the Evidence From Sugar-Sweetened Beverages Tells Us.
    Malik VS; Hu FB
    J Am Coll Cardiol; 2015 Oct; 66(14):1615-1624. PubMed ID: 26429086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fructose and metabolic diseases: new findings, new questions.
    Tappy L; Lê KA; Tran C; Paquot N
    Nutrition; 2010; 26(11-12):1044-9. PubMed ID: 20471804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans.
    Stanhope KL; Schwarz JM; Keim NL; Griffen SC; Bremer AA; Graham JL; Hatcher B; Cox CL; Dyachenko A; Zhang W; McGahan JP; Seibert A; Krauss RM; Chiu S; Schaefer EJ; Ai M; Otokozawa S; Nakajima K; Nakano T; Beysen C; Hellerstein MK; Berglund L; Havel PJ
    J Clin Invest; 2009 May; 119(5):1322-34. PubMed ID: 19381015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fructose-containing caloric sweeteners as a cause of obesity and metabolic disorders.
    Tappy L
    J Exp Biol; 2018 Mar; 221(Pt Suppl 1):. PubMed ID: 29514881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic effects of fructose and the worldwide increase in obesity.
    Tappy L; Lê KA
    Physiol Rev; 2010 Jan; 90(1):23-46. PubMed ID: 20086073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dietary sugars and de novo lipogenesis in non-alcoholic fatty liver disease.
    Moore JB; Gunn PJ; Fielding BA
    Nutrients; 2014 Dec; 6(12):5679-703. PubMed ID: 25514388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health outcomes of a high fructose intake: the importance of physical activity.
    Tappy L; Rosset R
    J Physiol; 2019 Jul; 597(14):3561-3571. PubMed ID: 31116420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physiological handling of dietary fructose-containing sugars: implications for health.
    Campos VC; Tappy L
    Int J Obes (Lond); 2016 Mar; 40 Suppl 1():S6-11. PubMed ID: 27001645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolism of sugars: A window to the regulation of glucose and lipid homeostasis by splanchnic organs.
    Tappy L
    Clin Nutr; 2021 Apr; 40(4):1691-1698. PubMed ID: 33413911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugary drinks in the pathogenesis of obesity and cardiovascular diseases.
    Brown CM; Dulloo AG; Montani JP
    Int J Obes (Lond); 2008 Dec; 32 Suppl 6():S28-34. PubMed ID: 19079277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does fructose consumption contribute to non-alcoholic fatty liver disease?
    Tappy L; Lê KA
    Clin Res Hepatol Gastroenterol; 2012 Dec; 36(6):554-60. PubMed ID: 22795319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies about sugars: results from systematic reviews and meta-analyses on obesity, cardiometabolic disease and diabetes.
    Khan TA; Sievenpiper JL
    Eur J Nutr; 2016 Nov; 55(Suppl 2):25-43. PubMed ID: 27900447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fructose-containing sugars, blood pressure, and cardiometabolic risk: a critical review.
    Ha V; Jayalath VH; Cozma AI; Mirrahimi A; de Souza RJ; Sievenpiper JL
    Curr Hypertens Rep; 2013 Aug; 15(4):281-97. PubMed ID: 23793849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.
    Taskinen MR; Söderlund S; Bogl LH; Hakkarainen A; Matikainen N; Pietiläinen KH; Räsänen S; Lundbom N; Björnson E; Eliasson B; Mancina RM; Romeo S; Alméras N; Pepa GD; Vetrani C; Prinster A; Annuzzi G; Rivellese A; Després JP; Borén J
    J Intern Med; 2017 Aug; 282(2):187-201. PubMed ID: 28548281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fructose Containing Sugars at Normal Levels of Consumption Do Not Effect Adversely Components of the Metabolic Syndrome and Risk Factors for Cardiovascular Disease.
    Angelopoulos TJ; Lowndes J; Sinnett S; Rippe JM
    Nutrients; 2016 Mar; 8(4):179. PubMed ID: 27023594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sugars, obesity, and cardiovascular disease: results from recent randomized control trials.
    Rippe JM; Angelopoulos TJ
    Eur J Nutr; 2016 Nov; 55(Suppl 2):45-53. PubMed ID: 27418186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fructose and risk of cardiometabolic disease.
    Bray GA
    Curr Atheroscler Rep; 2012 Dec; 14(6):570-8. PubMed ID: 22949106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fructose: it's "alcohol without the buzz".
    Lustig RH
    Adv Nutr; 2013 Mar; 4(2):226-35. PubMed ID: 23493539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.